Amicus Therapeutics (FOLD) Stock Price, Quote & News

Company Profile

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 662 2000

Fax: 609 662 2001

Website: amicusrx.com

Address:

47 Hulfish Street, Princeton, United States

Hawaiianinvesta Aug. 7 at 5:35 PM

$FOLD no folding here!

1 · Reply

Mikelonggggggggg Aug. 7 at 2:17 PM

$FOLD What are you doing!!!!!

0 · Reply

stonk_mojo Aug. 7 at 6:44 AM

$FOLD Biotech breaking 2-year downtrend at $12. Follow-through above $13.50 confirms reversal. Volume surge notable.

0 · Reply

Hognose Aug. 6 at 11:16 PM

$EXAS remember stocks like these, there are too many. Just buy AMZN GOOGL and like NVDA. Keep it simple and dont give these assholes your hard earned money like $EXAS $RXRX $FOLD $BMRN $JAZZ just buy good mega blue chips

0 · Reply

HorizonBull Aug. 6 at 2:07 PM

$FOLD is this price target given by morgan stanley on jul 17 at $108 is correct.

0 · Reply

HorizonBull Aug. 6 at 2:06 PM

$FOLD added 1000 at 6.88.

0 · Reply

NetworkNewsWire Aug. 6 at 1:02 PM

Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators $SNGX $AMGN $FOLD $TNXP $CTOR https://ibn.fm/x9cai

1 · Reply

TeeMan123 Aug. 4 at 6:57 PM

$FOLD Pfizer vs Biogen bidding war for amicus???

1 · Reply

Orlandotrader Aug. 4 at 5:36 PM

$FOLD Amicus Finally Turning the Corner. Started 1000.

0 · Reply

Hawaiianinvesta Aug. 4 at 5:32 PM

$FOLD i'm in, time to moon!

0 · Reply

Amicus Therapeutics: Going Beyond $1B Target Revenues Of Lead Products With Licensed DMX-200

Jul 31, 2025, 3:12 PM EDT - 7 days ago

Amicus Therapeutics, Inc. (FOLD) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 7:00 AM EDT - 8 days ago

Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates

Jul 28, 2025, 6:20 PM EDT - 10 days ago

In NCLA Amicus Win, Eleventh Circuit Vacates SEC Order Used to Fund Its Illegal Collection of Data

Jul 21, 2025, 7:00 AM EDT - 18 days ago

Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025

Jul 10, 2025, 8:00 AM EDT - 4 weeks ago

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term FOLD Investors to Contact the Firm

Jun 25, 2025, 7:00 AM EDT - 6 weeks ago

Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan

Jun 20, 2025, 5:03 PM EDT - 6 weeks ago

U.S. Supreme Court Decision Cites NCLA's Amicus Brief in Preserving Access to Federal Courts

Jun 16, 2025, 2:02 PM EDT - 7 weeks ago

The Association of American Physicians and Surgeons files an Amicus Brief in the Supreme Court in Support of the Right to Conversion Therapy

Jun 13, 2025, 6:23 PM EDT - 7 weeks ago

In NCLA Amicus Win, Supreme Court Revives Innocent Family's Suit over FBI's Wrong-House Raid

Jun 12, 2025, 4:16 PM EDT - 2 months ago

In NCLA Amicus Win, District Court Topples Kansas Dog Kennel No-Warrant Inspection Regime

Jun 12, 2025, 10:14 AM EDT - 2 months ago

Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma

Jun 3, 2025, 7:00 AM EDT - 2 months ago

New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve

May 30, 2025, 7:00 AM EDT - 2 months ago

Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025

May 7, 2025, 7:00 AM EDT - 3 months ago

Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference

May 1, 2025, 4:24 PM EDT - 3 months ago

Amicus Therapeutics, Inc. (FOLD) Q1 2025 Earnings Call Transcript

May 1, 2025, 7:00 AM EDT - 3 months ago

Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates

Apr 30, 2025, 7:12 PM EDT - 3 months ago

Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States

Apr 21, 2025, 7:00 AM EDT - 3 months ago

Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025

Mar 17, 2025, 10:21 AM EDT - 5 months ago

Amicus Therapeutics Is Very Attractive At Current Prices (Rating Upgrade)

Mar 6, 2025, 4:31 PM EST - 5 months ago

In NCLA Amicus Win, D.C. Circuit Recognizes President Trump's Right to Fire Principal Officer

Mar 3, 2025, 2:04 PM EST - 5 months ago

NCLA Amicus Brief Asks Fifth Circuit to Maintain Block Against Corporate Transparency Act

Feb 27, 2025, 7:00 AM EST - 5 months ago

Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025

Feb 19, 2025, 2:04 PM EST - 6 months ago

Amicus Therapeutics, Inc. (FOLD) Q4 2024 Earnings Call Transcript

Feb 19, 2025, 7:00 AM EST - 6 months ago

Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates

Feb 17, 2025, 5:59 PM EST - 6 months ago

Kuehn Law Encourages Investors of Amicus Therapeutics, Inc. to Contact Law Firm

Feb 10, 2025, 7:00 AM EST - 6 months ago

Amicus Therapeutics to Announce Full-Year 2024 Financial Results on February 19, 2025

Feb 3, 2025, 7:00 AM EST - 6 months ago

Amicus Therapeutics Announces Presentations and Posters at the 21st Annual WORLDSymposium™ 2025

Jan 23, 2025, 3:38 PM EST - 7 months ago

NCLA Amicus Brief Asks Fifth Circuit to Uphold Jury-Trial Rights in FDIC Enforcement Cases

Jan 13, 2025, 1:46 PM EST - 7 months ago

NCLA Amicus Brief Asks Supreme Court to Keep Unlawful Corporate Transparency Act Enjoined

Jan 13, 2025, 12:56 PM EST - 7 months ago

3 Oversold Biotech Names

AVDL JAZZ VKTX XBI

Jan 12, 2025, 4:00 PM EST - 7 months ago

Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook

Jan 2, 2025, 7:00 AM EST - 7 months ago

Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 30, 2024, 8:30 AM EST - 7 months ago

Fold, Inc. Announces Up To $30 Million Convertible Note Financing Backed by Bitcoin

Dec 27, 2024, 1:33 PM EST - 7 months ago

Amicus Therapeutics: Cheap Heading Into 2025

Dec 23, 2024, 3:43 PM EST - 8 months ago

NCLA Amicus Brief Asks Supreme Court to Read Judicial Review Statute Broadly, as Congress Wrote It

Dec 18, 2024, 1:09 PM EST - 8 months ago

NCLA Amicus Brief Asks Fifth Circuit to Uphold Block on Unconstitutional Corporate Transparency Act

Dec 13, 2024, 3:28 PM EST - 8 months ago

Retired Judges' Amicus Brief Supports Judge Newman in NCLA Suit Against Her Suspension

Dec 13, 2024, 2:10 PM EST - 8 months ago

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

IMRX

Dec 3, 2024, 1:14 PM EST - 8 months ago

NCLA Amicus Brief Asks Fifth Circuit to Overturn Banking Administration Board's Denial of Jury Trial

Nov 12, 2024, 7:04 PM EST - 9 months ago

NCLA Amicus Brief Asks Fifth Circuit to Overturn Currency Comptroller's Violation of Jury Trial Rights

Nov 6, 2024, 12:54 PM EST - 9 months ago

Amicus Therapeutics, Inc. (FOLD) Q3 2024 Earnings Call Transcript

Nov 1, 2024, 7:00 AM EDT - 10 months ago

Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024

Oct 28, 2024, 7:00 AM EDT - 10 months ago

Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024

Oct 21, 2024, 4:18 PM EDT - 10 months ago

American Citizens Abroad (ACA) joins amicus brief supporting voting by U.S. citizens overseas

Oct 21, 2024, 4:17 PM EDT - 10 months ago

3 Attractive Biotechs With Recent Positives

EXEL MRK TEVA XBI

Oct 18, 2024, 3:47 PM EDT - 10 months ago

Amicus: Teva Settlement Clears Revenue Path Forward For Galafold

Oct 17, 2024, 11:07 AM EDT - 10 months ago

Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug

TEVA

Hawaiianinvesta Aug. 7 at 5:35 PM

$FOLD no folding here!

1 · Reply

Mikelonggggggggg Aug. 7 at 2:17 PM

$FOLD What are you doing!!!!!

0 · Reply

stonk_mojo Aug. 7 at 6:44 AM

$FOLD Biotech breaking 2-year downtrend at $12. Follow-through above $13.50 confirms reversal. Volume surge notable.

0 · Reply

Hognose Aug. 6 at 11:16 PM

0 · Reply

HorizonBull Aug. 6 at 2:07 PM

$FOLD is this price target given by morgan stanley on jul 17 at $108 is correct.

0 · Reply

HorizonBull Aug. 6 at 2:06 PM

$FOLD added 1000 at 6.88.

0 · Reply

NetworkNewsWire Aug. 6 at 1:02 PM

Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators $SNGX $AMGN $FOLD $TNXP $CTOR https://ibn.fm/x9cai

1 · Reply

TeeMan123 Aug. 4 at 6:57 PM

$FOLD Pfizer vs Biogen bidding war for amicus???

1 · Reply

Orlandotrader Aug. 4 at 5:36 PM

$FOLD Amicus Finally Turning the Corner. Started 1000.

0 · Reply

Hawaiianinvesta Aug. 4 at 5:32 PM

$FOLD i'm in, time to moon!

0 · Reply

MGeronimo Aug. 4 at 5:02 PM

$FOLD should bounce off solid earnings

0 · Reply

Sealab_2020 Aug. 4 at 2:38 AM

Watching the following this week for multi-day swings $LYG Will watch for our hourly dips to take positions $AM Watching for breakout of key levels of 18.62 and 19.09 $IMAB Watching for breakout of key level of 2.66 $FOLD Watching for breakout of key levels of 6.4 and 6.7 $INDO Will wait for 5-EMA to cross over 20-EMA and then wait for hourly dips to take positions

2 · Reply

MGeronimo Aug. 2 at 2:01 AM

$FOLD IN AT 6.32

0 · Reply

valueforme Aug. 1 at 8:11 PM

$FOLD BofA post earnings commentary

0 · Reply

valueforme Aug. 1 at 5:24 PM

$FOLD If you want to follow the remaining legal battle with generic manufacturers, you need to watch this one on Pacer: 1:22-cv-01461-CJB Amicus Therapeutics US, LLC et al v. Teva Pharmaceuticals USA, Inc. et al It's pretty active recently @AttorneysRealty Will, if you have time, what can you say about chances of Aurobindo to get a positive summary judgement here? Note that Teva has settled before https://ir.amicusrx.com/news-releases/news-release-details/amicus-therapeutics-announces-settlement-galafoldr-migalastat

1 · Reply

ZacksResearch Aug. 1 at 4:56 PM

$FOLD missed on Q2 earnings — but revenue told a different story 📈 Strong sales of Galafold and Pombiliti + Opfolda helped the company beat revenue estimates, even as earnings fell short. Full breakdown here 👉 https://www.zacks.com/stock/news/2649843/fold-q2-earnings-miss-mark-revenues-beat-on-higher-product-sales?cid=sm-stocktwits-2-2649843-teaser-5513&ADID=SYND_STOCKTWITS_TWEET_2_2649843_TEASER_5513

0 · Reply

valueforme Aug. 1 at 3:56 PM

$FOLD Nothing bad to say after reading 10-Q. Staying here for GAAP profitability and potential DMX200 surprises

0 · Reply

ZacksResearch Aug. 1 at 3:26 PM

$FOLD misses Q2 earnings estimates but beats on revenue! 📉📈 Adjusted EPS came in at 1 cent, missing the Zacks Consensus Estimate of 2 cents, while revenues surged 22% year over year on a reported basis to $154.7M, topping estimates thanks to strong sales of Galafold and new combo drug Pombiliti + Opfolda. See what makes the investment case strong for Amicus 👉 https://www.zacks.com/stock/news/2649843/fold-q2-earnings-miss-mark-revenues-beat-on-higher-product-sales?cid=sm-stocktwits-2-2649843-body-5421&ADID=SYND_STOCKTWITS_TWEET_2_2649843_BODY_5421

0 · Reply

NiceBuzz Aug. 1 at 3:03 PM

$FOLD I sold abvx for 600 percent gain. You’re trying to get in it now and bashing fold? Only thing on the ER call I didn’t like was no revision to 25 outlook.

1 · Reply

Hognose Aug. 1 at 9:48 AM

$FOLD in a down trend for 5 years. Nice

0 · Reply

Hognose Aug. 1 at 9:47 AM

$FOLD another big pos pharmaceutical company. Big surprise

0 · Reply

Nosh Jul. 31 at 7:52 PM

$FOLD Looking to add as she approaches $5.50 again.

1 · Reply

Market Cap	2.14B
Revenue (ttm)	528.30M
Net Income (ttm)	-56.11M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	349.50
Profit Margin	-10.62%
Debt to Equity Ratio	1.92

Volume	4,078,400
Avg Vol	4,878,352
Day's Range	N/A - N/A
Shares Out	308.24M
Stochastic %K	76%
Beta	0.53
Analysts	Strong Sell
Price Target	$16.45